open access

Vol 9, No 5 (2004)
Published online: 2004-01-01
Submitted: 2004-03-30
Get Citation

Advances in the treatment of indolent lymphomas

Tomasz Wróbel, Grzegorz Mazur
DOI: 10.1016/S1507-1367(04)71024-X
·
Rep Pract Oncol Radiother 2004;9(5):169-172.

open access

Vol 9, No 5 (2004)
Published online: 2004-01-01
Submitted: 2004-03-30

Abstract

Non-Hodgkin's lymphomas (nHL) are a heterogenous group of lymphoid malignancies with a different pattern of behaviour and response to treatment. In Europe and North America mainly B-cell lymphomas (86%) are observed. Indolent lymphomas are lymphoproliferative diseases with a relatively good prognosis and long natural history. They usually affect elderly people and more than 90% of cases are diagnosed in advanced stages of the disease. Forty percent all cases of nHL are indolent lymphomas. Indolent lymphomas are curable only in their early stages when radiotherapy is the treatment of choice. In advanced stages chemotherapy is used. However, up till now aggressive chemotherapy does not improve the overall survival rate and it leads to serious adverse events. This article presents current options of management of indolent nHL, especially using purine analogues and monoclonal antibodies.

Purine analogues (fludarabine, 2-chloro-2′desoxyadenosine-2CdA) are thought to be very promising agents as they induce apoptosis and have cytotoxic activity against noncycling lymphocytes which dominate in indolent lymphomas histology. In recent years monoclonal antibodies against antigens present on the lymphoma cells such as rituximab (Mabthera) antiCD20 or alemtuzumab (MabCampath) antiCD52 have been widely used.

Abstract

Non-Hodgkin's lymphomas (nHL) are a heterogenous group of lymphoid malignancies with a different pattern of behaviour and response to treatment. In Europe and North America mainly B-cell lymphomas (86%) are observed. Indolent lymphomas are lymphoproliferative diseases with a relatively good prognosis and long natural history. They usually affect elderly people and more than 90% of cases are diagnosed in advanced stages of the disease. Forty percent all cases of nHL are indolent lymphomas. Indolent lymphomas are curable only in their early stages when radiotherapy is the treatment of choice. In advanced stages chemotherapy is used. However, up till now aggressive chemotherapy does not improve the overall survival rate and it leads to serious adverse events. This article presents current options of management of indolent nHL, especially using purine analogues and monoclonal antibodies.

Purine analogues (fludarabine, 2-chloro-2′desoxyadenosine-2CdA) are thought to be very promising agents as they induce apoptosis and have cytotoxic activity against noncycling lymphocytes which dominate in indolent lymphomas histology. In recent years monoclonal antibodies against antigens present on the lymphoma cells such as rituximab (Mabthera) antiCD20 or alemtuzumab (MabCampath) antiCD52 have been widely used.

Get Citation

Keywords

non-Hodgkin' s lymphomas; treatment; purine analogues; monoclonal antibodies

About this article
Title

Advances in the treatment of indolent lymphomas

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 9, No 5 (2004)

Pages

169-172

Published online

2004-01-01

DOI

10.1016/S1507-1367(04)71024-X

Bibliographic record

Rep Pract Oncol Radiother 2004;9(5):169-172.

Keywords

non-Hodgkin's lymphomas
treatment
purine analogues
monoclonal antibodies

Authors

Tomasz Wróbel
Grzegorz Mazur

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl